Literature DB >> 33641720

Osimertinib Should be the Standard of Care for the Adjuvant Therapy of Stage IB to IIIA EGFR-Mutant NSCLC.

Jordi Remon1, Lizza E L Hendriks2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33641720     DOI： 10.1016/j.jtho.2020.11.027

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  2 in total

1.  The Presence of EGFR T790M in TKI-Naïve Lung Cancer Samples of Patients Who Developed a T790M-Positive Relapse on First or Second Generation TKI Is Rare.

Authors:  Weiting Li; Klaas Kok; Geok Wee Tan; Pei Meng; Mirjam Mastik; Naomi Rifaela; Frank Scherpen; T Jeroen N Hiltermann; Harry J M Groen; Anthonie J van der Wekken; Anke van den Berg
Journal:  Cancers (Basel)       Date:  2022-07-19       Impact factor: 6.575

2.  Predictive value of the hemoglobin, albumin, lymphocyte, and platelet (HALP) score and lymphocyte-to-monocyte ratio (LMR) in patients with non-small cell lung cancer after radical lung cancer surgery.

Authors:  Baoqian Zhai; Jia Chen; Jiacheng Wu; Lei Yang; Xiaoli Guo; Jingjing Shao; Hong Xu; Aiguo Shen
Journal:  Ann Transl Med       Date:  2021-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.